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Abstract. The usefulness of the field‑in‑field with two 
reference points (FIF w/ 2RP) method, in which the dose 
reference points are set simultaneously at two positions in 
the irradiation field and the high‑dose range is completely 
eliminated, was examined in the present study with the aim of 
decreasing acute skin toxicity in adjuvant breast radiotherapy 
(RT). A total of 573 patients with breast cancer who underwent 
postoperative whole breast RT were classified into 178 cases 
with wedge (W) method, 142 cases with field‑in‑field without 
2 reference points (FIF w/o 2RP) method and 253 cases with 
FIF w/ 2RP method. Using the FIF w/ 2RP method, the 
high‑dose range was the lowest among the three irradiation 
methods. The planning target volume (PTV) V105% and the 
breast PTV for evaluation (BPe) V105% decreased to 0.09 and 
0.10%, respectively. The FIF w/ 2RP method vs. the FIF w/o 
2RP method had a strong association (η) with PTV V105% 
(η=0.79; P<0.001) and BPe V105% (η=0.76; P<0.001). The FIF 
w/ 2RP method had a significant impact on lowering the skin 
toxicity grade in weeks 3 and 4, and increasing the occurrence 
of skin toxicity grade 0. The FIF w/ 2RP method vs. the 
W method had a moderate association with skin toxicity grade 
at week 3 (η=0.49; P<0.001). Using the FIF w/ 2RP method, 
the high‑dose range V105% of the target decreased to 0%, 
and skin adverse events were decreased in conjunction. For 
patients with early‑stage breast cancer, particularly patients 
with relatively small‑sized breasts, the FIF w/ 2RP method 
may be an optimal irradiation method.
Introduction
For women with early‑stage breast cancer, whole breast radio‑
therapy (WBRT) after breast‑conserving surgery (BCS) is a 
longstanding standard practice. WBRT reduces the risk of 
locoregional and distant first recurrence by 50%, and reduces 
breast cancer death by ~1/6 (1,2). However, most patients 
with breast cancer who undergo adjuvant radiotherapy (RT) 
are affected by skin toxicities (3). During RT treatment, 
these skin toxicities cause physical discomfort and emotional 
distress, and therefore negatively affect the patients' quality of 
life (4). In consequence, previous studies investigated factors 
associated with an increased risk of developing acute skin 
toxicities. Dose distribution and resulting dosimetric param‑
eters (in particular high‑dose ranges of >105, >107 and >110% 
within the target volume) are RT treatment procedure‑related 
factors, reported to be significantly associated with an 
increased risk of developing skin toxicities (5‑8).
In modern RT, field‑in‑field (FIF) techniques are consid‑
ered the standard‑of‑care when three‑dimensional conformal 
RT (3D‑CRT) treatment planning is available (5,9). However, 
using the FIF for patients who have relatively small‑sized 
breasts results in high‑dose areas remaining in the irradiation 
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field around the reference point. Therefore, in our institution, 
we implemented a new FIF technique, the field‑in‑field with 
2 reference points (FIF w/ 2RP) method, aimed at improving 
dosimetric parameters and thus reducing high‑dose ranges and 
subsequent skin toxicities.
The current study sought to examine the usefulness of this 
new irradiation method. We performed a comparative analysis 
of dosimetric parameters of three irradiation methods including 
the FIF w/ 2RP method and two other irradiation methods, the 
wedge (W) method and the field‑in‑field without 2 reference 
points (FIF w/o 2RP) method, as control. Furthermore, we 
assessed radiation‑induced skin toxicities. We then inves‑
tigated the association of each irradiation method and skin 
toxicities.
Materials and methods
Patients. Between April 2008 and December 2016, 577 
females with early‑stage breast cancer treated at Okayama 
University Hospital with BCS and adjuvant RT were evaluated. 
These patients were selected from 723 consecutive females 
with early‑stage breast cancer. Exclusion criteria were simul‑
taneous bilateral breast cancer, treatment with regional nodal 
irradiation and treatment using hypo‑fractionated irradiation. 
Furthermore, four patients treated without the use of wedge 
filters or the FIF method were excluded from this study due to 
insufficient sample size. Finally, data regarding 573 patients, 
aged 24‑82 years (mean, 55 years), were evaluated. Patients 
provided written informed consent for undergoing RT and 
using their anonymous data for scientific studies. This study 
was conducted in accordance with the Declaration of Helsinki, 
as revised in 2013.
Radiation treatment. Each patient received WBRT in 
25 consecutive fractions of 2 Gy to a total prescribed dose 
of 50 Gy. In total, 271 patients received a sequential boost 
of 10 or 16 Gy to the tumor bed. Free‑breathing computed 
tomography (CT) acquisition was performed with an Asteion 
Super4 Edition multi‑slice CT scanner (Toshiba Corporation) 
and reconstructed with 2 mm‑thick slices. To set the irra‑
diation field, radio‑opaque markers were placed on external 
landmarks; the sternal notch, the midline, the mid‑axillary 
line, 1 cm below the infra‑mammary fold, surgical scars, the 
nipple and the margin of palpable breast tissue; at the acquisi‑
tion of the CT scan to facilitate contouring segmentation of the 
CT dataset. CT images were then transferred to the treatment 
planning system CMS Xio Ver 4.3.4 (Computerized Medical 
Systems, Inc.).
The planning target volume (PTV) was defined 
three‑dimensionally as 5 mm inside the previously set irra‑
diation field, excluding the part outside the patient and the 
first 5 mm of tissue under the skin, and posteriorly limited 
no deeper to the anterior surface of the ribs excluding the 
boney thorax and lung. Breast PTV Eval (BPe) was deter‑
mined according to the clinical research protocol Radiation 
Therapy Oncology Group (RTOG) 1005 (10) and its defined 
clinical target volume (CTV) and PTV. This BPe volume was 
used for breast volume evaluation. Contoured organs at risk 
(OARs) were the lung and the heart. The heart and the axillary 
lymph nodes levels I, II and III were countered according to 
the RTOG‑endorsed consensus guidelines for delineation 
of target and normal structures for breast cancer (11). These 
target contours were then checked and modified to be included 
within the previously set irradiation field to be 3D‑CRT treat‑
ments. Beam energies were 4, 6 and 10 MV by LINEACS 
(Mevatron M2/6327, PRIMUS High Energy KD2/7467 and 
ONCOR High Energy ONCR‑K; Toshiba Corporation).
Three irradiation methods were performed: i) W method 
was used for 178 patients. The RP was set at the level of the 
nipple or at the mid‑level between the upper and lower edges of 
the irradiation field. Physical wedges in the opposing tangential 
beams were used to improve target dose distribution. For some 
patients, to avoid hot spots, dose distribution was optimized by 
adding an extra tangent FIF; ii) the FIF w/o 2RP method was 
used for 142 patients. Two opposed tangential fields were set 
up without wedges. The RP was set at the mid‑level between 
the upper and lower edges of the irradiation field or 2 cm apart 
from the deepest point and upper edge of the irradiation field. 
The main field was copied as subfields and the multileaf colli‑
mators (MLCs) were manipulated to shield the areas of the 
breast receiving a high dose. However, these MLCs were not 
allowed to block within 2 cm of the RP; and iii) the FIF w/ 2RP 
method was used for 253 patients. Two RPs were set for each 
patient; one RP for the main beam at a point 2 cm apart from 
the deepest point and upper edge of the irradiation field, and 
another RP for the FIF at the mid‑level between the upper and 
lower edges of the irradiation field. As one RP was used in the 
FIF w/o 2RP method, the MLCs could not be inserted in the 
range of 2 cm around the RP, which resulted in the high‑dose 
area remaining close to that RP. For patients who have rela‑
tively small‑sized breasts, this can be problematic, as it results 
in a high‑dose area around that RP. Therefore, in the FIF w/ 
2RP method, the RPs were set simultaneously at two places 
in the irradiation field, and high‑dose areas were sequentially 
shielded and completely eliminated by the MLCs. Patients 
treated with the W method and the FIF w/o 2RP method were 
considered as control patients.
Dosimetric analysis. A dose distribution in the PTV and BPe 
of 95‑107% according to ICRU criteria was obtained while 
lowering OARs doses as much as possible. The dosimetric 
parameters recorded for all plans, including PTV and BPe, 
were mean dose, V0‑95% (the volume percentage receiving 
less than 95% of the prescribed dose), V95‑107% (the volume 
percentage receiving between 95 and 107% of the prescribed 
dose), V107% (the volume percentage receiving more than 
107% of the prescribed dose) and V105% (the volume 
percentage receiving 105% or more of the prescribed dose). 
Dose distribution in the axillary lymph nodes was evaluated 
using the mean axillary lymph nodes levels I, II and III 
doses. The OAR constraints used for planning for the ipsilat‑
eral lung were the mean ipsilateral lung dose (MLD), ipV20 
(the lung volume percentage receiving ≥20 Gy) and ipV30 
(the lung volume percentage receiving ≥30 Gy), while those 
for the heart were the mean heart dose (MHD), V10 (the 
heart volume percentage receiving ≥10 Gy), V20 (the heart 
volume percentage receiving ≥20 Gy), and the maximum 
doses to the left anterior descending coronary artery (LAD), 
the circumflex coronary artery (CCA) and the right coronary 
artery (RCA).
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Acute toxicity grading for skin. Patients were evaluated on a 
weekly basis for acute skin toxicities. The highest grade of 
radiation dermatitis for each treated breast was prospectively 
recorded at each on treatment during the 5 or 6 weeks of treat‑
ment and at the follow‑up visit at the week 6 or 7 for patients 
who received RT without or with boost, respectively, using the 
National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE) v3.0 grading criteria (12). The 
NCI CTCAE describes grade 0 as ‘no reaction’, grade 1 as 
‘faint erythema or dry desquamation’, grade 2 as ‘moderate to 
brisk erythema, patchy moist desquamation mostly confined to 
skin folds and creases and moderate edema’, grade 3 as ‘moist 
desquamation other than skin folds or creases and bleeding 
induced by minor trauma or abrasion’ and grade 4 as ‘skin 
necrosis or ulceration of full thickness of the dermis, sponta‑
neous bleeding from involved site’ (3,12). To ensure standard 
grading of skin toxicities for study purposes, all information 
regarding toxicity grade in individual patient were recorded 
and reviewed by a single experienced radiation oncologist.
Data collection and statistical analysis. Demographic char‑
acteristics and clinical tumor characteristics were recorded 
for each patient. Tumor site was defined according to the 
International Classification of Diseases for Oncology (third 
edition) (13). Each radiation treatment plan was assessed, and 
dosimetric parameters were analyzed using a dose‑volume 
histogram. For this study, acute toxicity grading for skin 
within the first 5 weeks of treatment was analyzed.
Statistical analyses were performed using Bell Curve for 
Excel (Social Survey Research Information Co., Ltd.) and SPSS 
software v27.0 (IBM Corp.). Analyses of differences in the 
baseline characteristics, the RT characteristics, the skin toxicity 
grade throughout the RT treatment and the maximum skin 
toxicity grade during the 5 weeks of RT treatment according to 
the type of irradiation method used were conducted using the 
Kruskal‑Wallis test with Dunn's test and the χ2 test. The correla‑
tion between the irradiation methods and the dose‑distribution 
factors was examined to assess the impact of irradiation methods 
on the dose‑distribution factors, using Eta correlation ratio (η). 
The correlation between the skin toxicity grade and patients' 
baseline characteristics was analyzed using η and Spearman's 
correlation coefficient (rs), and the correlation between the skin 
toxicity grade and irradiation methods was analyzed using η. 
The following proposed guidelines were used for interpreting the 
absolute values of η and rs: 0.00‑0.19, markedly weak; 0.20‑0.39, 
weak; 0.40‑0.59, moderate; 0.60‑0.79, strong; and 0.80‑1.00, 
markedly strong. Data are presented as the mean ± SD, n (%), 
η or rs values. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Baseline characteristics according to the irradiation methods 
are detailed in Table I. Age, tumor site, breast volume or 
separation did not show statistically significant differences 
between the three different irradiation methods (Table I).
Dosimetric analysis. RT characteristics according to the irra‑
diation methods are detailed in Table II. PTV volume did not 
show a statistically significant difference between the three 
different irradiation methods. However, a significant impact 
of the irradiation method was observed on PTV and BPe 
dosimetric parameters, the mean dose, V0‑95%, V95‑107%, 
V107% and V105%. The volumes of the PTV and BPe 
receiving ≥105% of the prescribed dose were the lowest when 
using the FIF w/ 2RP method, with mean ± standard devia‑
tion (SD) values of 0.09±0.75 and 0.10±0.90, respectively. The 
mean axillary lymph nodes levels I, II and III doses were inter‑
mediate when using the FIF w/ 2RP method, with mean ± SD 
values of 3,278±822, 1,455±1,127 and 427±528, respectively. 
OAR constraints showed statistically significant differences 
between three different irradiation methods. The MHD, and 
the maximum doses to the CCA and the RCA were the lowest 
when using the FIF w/ 2RP method, with mean ± SD values of 
248±76, 201±32 and 212±34, respectively. However, the heart 
V10 and V20, and the maximum doses to the LAD were inter‑
mediate when using the FIF w/ 2RP method, with mean ± SD 
values of 3.0±2.1, 1.6±1.5 and 3,123±1,334, respectively. 
Nevertheless, the MLD, ipV20 and ipV30 were the highest 
when using the FIF w/ 2RP method, with mean ± SD values of 
771±198, 14±5 and 11±4, respectively (Table II).
Table III shows that the irradiation methods strongly 
affected the dose distribution factors. There were strong 
associations between all irradiation methods and the volumes 
of the PTV and BPe receiving ≥105% of the prescribed dose 
with (η=0.62, P<0.001) and (η=0.61, P<0.001), respectively. 
The strongest associations were found when comparing the 
FIF w/ 2RP method vs. the FIF w/o 2RP method for PTV 
V105% (η=0.79, P<0.001) and BPe V105% (η=0.76, P<0.001). 
Other dose distribution factors were less affected by the irra‑
diation methods, with markedly weak to moderate η values. 
For the heart, all irradiation methods had a weak association 
with MHD (η=0.26, P<0.001), and moderate associations 
with maximum doses to the CCA (η=0.45, P<0.001) and to 
the RCA (η=0.43, P<0.001). The strongest associations were 
found when comparing the FIF w/ 2RP method vs. the W 
method for MHD (η=0.29, P<0.001), maximum doses to the 
CCA (η=0.50, P<0.001) and to the RCA (η=0.47, P<0.001). For 
the lung, all irradiation methods had weak associations with 
MLD (η=0.28, P<0.001), ipV20 (η=0.31, P<0.001) and ipV30 
(η=0.34, P<0.001). The strongest associations were found 
when comparing the FIF w/ 2RP method vs. the W method for 
MLD (η=0.28, P<0.001), ipV20 (η=0.30, P<0.001) and ipV30 
(η=0.33, P<0.001).
Skin toxicity analysis. All irradiation methods were well 
tolerated, since no case of treatment interruption due to acute 
skin toxicity neither grade 3 skin toxicities were documented 
(Figs. 1 and 2).
The association between the time course of the RT and 
the mean skin toxicity grade registered at weeks 1‑5, and 
the maximum skin toxicity grade during the 5 weeks of RT 
treatment for each irradiation method are shown in Fig. 1. The 
occurrence and mean skin toxicity grade increased from the 
start of the RT for all the irradiation methods, especially after 
3 weeks of RT. In weeks 3 and 4, the FIF w/ 2RP method 
had a significant impact on lowering the skin toxicity mean 
grade. Kruskal‑Wallis test showed that there were significant 
differences in the skin toxicity median grade during weeks 2 
to 5 (Fig. 1).
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The percentage of patients according to the maximum 
skin toxicity grade during the 5 weeks of RT treatment for 
each irradiation method is summarized in Fig. 2. For the 
three irradiation methods, the maximum skin toxicity grade 
recorded was grade 2. The irradiation methods were signifi‑
cantly associated with the appearance of adverse effects. The 
use of the FIF w/ 2RP method increased the occurrence of 
grade 0 skin toxicity. Grade 0 was observed in 2 (1.1%), 0 
(0.0%) and 14 (5.5%) cases, respectively, for the W, FIF w/o 
2RP and FIF w/ 2RP methods. Grade 0 for the FIF w/ 2RP 
method was significantly higher compared to the other irradia‑
tion methods.  Furthermore, the use of the FIF w/ 2RP method 
decreased the occurrence of grade 1 skin toxicity. Grade 1 was 
observed in 168 (94.4%), 139 (97.9%) and 231 (91.3%) cases, 
respectively, for the W, FIF w/o 2RP and FIF w/ 2RP methods. 
However, grade 2 skin toxicity had an intermediate percentage 
when using the FIF w/ 2RP method. Grade 2 was observed in 
8 (4.5%), 3 (2.1%) and 8 (3.2%) cases, respectively, for the W, 
FIF w/o 2RP and FIF w/ 2RP methods.
For associations related to skin toxicity grade, results were 
examined at the following three time points: Week 3, week 4 
and maximum skin toxicity grade during the 5 weeks of RT 
treatment. As shown in Fig. 1, the skin toxicity grades from the 
start of the RT treatment to the 2nd week were low; moreover, 
the skin toxicity grade at week 5 and the maximum grade 
during the 5 weeks of RT treatment were similar. Therefore, 
associations of skin toxicity grade were examined at these 
three time points.
The association between patients' baseline characteristics 
and skin toxicity grade was analyzed for all patients. Most 
significant associations were observed in the following baseline 
characteristics: Breast volume factors (BPe volume, separation 




Variable All irradiation methods W FIF w/o 2RP FIF w/ 2RP P‑value
Patients, n 573 178 142 253 
Mean age ± SD, years 55±11 54±11 55±12 55±11 P=0.38a
Tumor site, n (%)     P=0.29b
  Upper‑inner quadrant 161 (28.1) 47 (26.4) 48 (33.8) 66 (26.1) 
  Lower‑inner quadrant 50 (8.7) 18 (10.1) 8 (5.6) 24 (9.5) 
  Upper‑outer quadrant 278 (48.5) 81 (45.5) 64 (45.1) 133 (52.6) 
  Lower‑outer quadrant 55 (9.6) 23 (12.9) 14 (9.9) 18 (7.1) 
  Central portion  29 (5.1) 9 (5.1) 8 (5.6) 12 (4.7) 
Mean BPe ± SD, cm3 442±254 457±271 428±244 439±247 P=0.77a




Variable All irradiation methods W FIF w/o 2RP FIF w/ 2RP P‑value
Patients, n 296 89 70 137
Mean age ± SD, years 55±11 55±11 57±11 55±11 P=0.26a
Tumor site, n (%)      P=0.75b
  Upper‑inner quadrant 82 (27.7) 26 (29.2) 23 (32.9) 33 (24.1) 
  Lower‑inner quadrant 30 (10.1) 11 (12.4) 4 (5.7) 15 (10.9) 
  Upper‑outer quadrant  149 (50.3) 42 (47.2) 34 (48.6) 73 (53.3) 
  Lower‑outer quadrant 16 (5.4) 6 (6.7) 4 (5.7) 6 (4.4) 
  Central portion  19 (6.4) 4 (4.5) 5 (7.1) 10 (7.3) 
Mean BPe ± SD, cm3 442±253 471±255 430±260 429±249 P=0.38a
Mean separation ± SD, cm 18.9±2.6 19.1±2.5 18.6±2.7 18.9±2.5 P=0.37a
The data are presented as the mean ± SD or n (%). Left‑sided patients refers to patients who received left‑sided breast radiotherapy. Tumor site 
was defined according to the International Classification of Diseases for Oncology (third edition). Separation (cm) was defined as the distance 
along the posterior edge of the tangent fields at the nipple level. aKruskal‑Wallis test; b 2 test. W, wedge; FIF w/o 2RP, field‑in‑field without 
2 reference points; FIF w/ 2RP, field‑in‑field with 2 reference points; BPe, breast planning target volume evaluation.
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Variable W  FIF w/o 2RP FIF w/ 2RP P‑valuea 
Patients, n 178 142 253 
Target    
  PTV    
    Volume, cm3 592±324 573±303 571±304 P=0.93
    Mean dose, cGy 4,924±84 5,011±65 4,952±45 P<0.001 (P<0.01c, P<0.001b,d)
    V0‑95, % 15±8 10±7 13±7 P<0.001 (P<0.05c, P<0.001b,d)
    V95‑107, % 84±8 90±7 87±7 P<0.001 (P<0.01c, P<0.001b,d)
    V107, % 0.52±1.50 0.27±0.28 0.00±0.01 P<0.001 (P<0.001b‑d)
    V105, % 3.50±4.88 6.63±3.96 0.09±0.75 P<0.001 (P<0.001b‑d)
  Breast PTV evaluation    
    Mean dose, cGy 4,969±62 5,043±60 4,980±48 P<0.001 (P<0.001b,d)
    V0‑95, % 10±6 5±5 8±7 P<0.001 (P<0.01c, P<0.001b,d)
    V95‑107, % 90±6 95±5 92±7 P<0.001 (P<0.001b‑d)
    V107, % 0.42±1.45 0.25±0.35 0.00±0.01 P<0.001 (P<0.001b‑d)
    V105, % 3.24±4.86 6.92±4.56 0.10±0.90 P<0.001 (P<0.001b‑d)
  Axillary lymph node    
    Mean dose, cGy    
    Level I 2,928±717 3,529±750 3,278±822 P<0.001 (P<0.05d, P<0.001b,c)
    Level II 1,356±1,029 1,726±1,330 1,455±1,127 P=0.10
    Level III 357±399 508±566 427±528 P<0.05 (P<0.05b)
Organ at risk: Lung    
  ip mean dose (cGy) 659±177 655±200 771±198 P<0.001 (P<0.001c,d)
  ipV20 (%) 11±4 11±5  14±5  P<0.001 (P<0.001c,d)
  ipV30 (%) 8±4 8±4 11±4 P<0.001 (P<0.001c,d)
B, Left‑sided patients    
 Irradiation method
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Variable W  FIF w/o 2RP FIF w/ 2RP P‑valuea
Patients, n 89 70 137 
Target    
  PTV    
    Volume, cm3 610±322 588±325 555±300 P=0.45
Organ at risk: Heart    
  Mean dose, cGy 300±99 257±90 248±76 P<0.001 (P<0.01b, P<0.001c)
  V10, % 3.8±2.9 2.9±2.6  3.0±2.1 P<0.05 (P<0.05b)
  V20, % 2.0±2.1 1.4±1.8 1.6±1.5 P=0.08
  LAD max, cGy 3,546±1,228 2,931±1,490 3,123±1,334 P<0.05 (P<0.05b,c)
  CCA max, cGy 239±32 212±31 201±32 P<0.001 (P<0.001b,c)
  RCA max, cGy 262±59 228±39 212±34 P<0.001 (P<0.01d, P<0.001b,c)
The data are presented as the mean ± SD. Left‑sided patients refers to patients who received left‑sided breast radiotherapy. aW vs. FIF w/o 2RP 
vs. FIF w/ 2RP via Kruskal‑Wallis test; bW vs. FIF w/o 2RP; cW vs. FIF w/ 2RP; and dFIF w/o 2RP vs. FIF w/ 2RP via Dunn's test. W, wedge; 
FIF w/o 2RP, field‑in‑field without 2 reference points; FIF w/ 2RP, field‑in‑field with 2 reference points; PTV, planning target volume; ip, ipsi‑
lateral; LAD, left anterior descending artery; CCA, common carotid artery; RCA, right coronary artery; max, maximum dose.
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and PTV volume) and weight exhibited markedly weak posi‑
tive correlations with the maximum skin toxicity grade during 
the 5 weeks of RT treatment. The rs values were as follows 
for BPe volume (rs=0.17, P<0.01), separation (rs=0.17, P<0.01), 
PTV volume (rs=0.18, P<0.01) and weight (rs=0.17, P<0.01). 
Tumor site exhibited markedly weak associations with the 
skin toxicity grade at weeks 3 and 4. The η values were as 
follows for tumor site at week 3 (η=0.16, P<0.05) and at week 4 
(η=0.16, P<0.05).
Table IV shows the association between irradiation 
methods and skin toxicity grade. The impact of the irradiation 
methods differed with the time course of the RT treatment. 
Associations between all irradiation methods and the skin 
toxicity grade were moderate at week 3 (η=0.46, P<0.001), 
weak at week 4 (η=0.33, P<0.001) and markedly weak for the 
maximum skin toxicity grade during the 5 weeks of RT treat‑
ment (η=0.11, P<0.05). Significant associations were found at 
all time points in the FIF w/ 2RP method vs. the W method 
group, but only at weeks 3 and 4 in the FIF w/ 2RP method vs. 
the FIF w/o 2RP method group.
Discussion
In accordance with the modern RT goal of reducing skin 
toxicity and improving the quality of life of patients with 
early‑stage breast cancer, our study aimed to present an irra‑
diation method that is both clinically practical and effective in 
achieving lower skin toxicity rates. This study showed that the 
Table III. Association between irradiation methods and dose‑distribution factors.
 All irradiation W vs. FIF W vs. FIF FIF w/o 2RP vs. 
Variable methods w/o 2RP w/ 2RP FIF w/ 2RP
Target    
  High dose region, %    
    PTV V107 0.26a 0.11b 0.26a 0.61a
    PTV V105  0.62a 0.33a 0.47a 0.79a
    BPe V107 0.21a 0.08 (P=0.17) 0.21a 0.49a
    BPe V105 0.61a 0.36a 0.44a 0.76a
  Adequate dose region, %    
    PTV V95‑107 0.28a 0.36a 0.17a 0.21a
    BPe V95‑107 0.28a 0.40a 0.14a 0.23a
  Low dose region, %    
    PTV V0‑95 0.26a 0.33a 0.13b 0.22a
    BPe V0‑95 0.27a 0.38a 0.11b 0.24a
  Mean dose, cGy    
    PTV  0.45a 0.49a 0.21a 0.47a
    BPe  0.47a 0.52a 0.10b 0.50a
  Axillary lymph node mean dose, cGy    
    Level I  0.28a 0.38a 0.22a 0.15b
    Level II 0.12b 0.16b 0.05 (P=0.35) 0.11b
    Level III  0.11b 0.15b 0.07 (P=0.14) 0.07 (P=0.16)
Organs at risk    
  Lung    
    ip mean dose, cGy 0.28a 0.01 (P=0.84) 0.28a 0.27a
    ipV20, % 0.31a 0.02 (P=0.75) 0.30a 0.30a
    ipV30, % 0.34a 0.00 (P=0.94) 0.33a 0.31a
  Heart (left‑sided patients)    
    Mean dose, cGy 0.26a 0.22b 0.29a 0.05 (P=0.45)
    V10, % 0.16b 0.17b 0.16b 0.03 (P=0.68)
    V20, % 0.13 (P=0.07) 0.15 (P=0.06) 0.12 (P=0.06) 0.05 (P=0.50)
    LAD max, cGy 0.17b 0.22b 0.16b 0.07 (P=0.35)
    CCA max, cGy 0.45a 0.39a 0.50a 0.17b
    RCA max, cGy 0.43a 0.31a 0.47a 0.20b
The data are presented as the Eta correlation ratio (η) values. Left‑sided patients refers to patients who received left‑sided breast radiotherapy. 
aP<0.001 and bP<0.05 via Eta correlation ratio test. W, wedge; FIF w/o 2RP, field‑in‑field without 2 reference points; FIF w/ 2RP, field‑in‑field 
with 2 reference points; PTV, planning target volume; BPe, breast PTV evaluation; ip, ipsilateral; LAD, left anterior descending artery; 
CCA, common carotid artery; RCA, right coronary artery; max, maximum dose.
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FIF w/ 2RP method, compared with the W and FIF w/o 2RP 
methods, was advantageous in maintaining a homogeneous 
dose distribution while reducing high‑dose areas in the target 
and doses at OARs, and consequently lowering skin toxicity 
occurrence and grades.
For WBRT, several RT techniques are available to achieve 
a uniform and standardized dose throughout the whole breast. 
The progression of RT techniques and delivery systems, 
including intensity‑modulated radiation therapy (IMRT), volu‑
metric modulated arc therapy (VMAT) and deep inspiration 
breath‑hold methods, improved dose homogeneity and enabled 
a better dose distribution. However, the 3D‑CRT treatment 
planning is a widespread implemented system, and when 
used in adjunction to the FIF technique, enables an improved 
homogeneity in the irradiated volume and lowers high‑dose 
areas (9,14).
Wright et al (15) evaluated 392 patients, 83% of which were 
treated with conventionally fractionated scheme and 17% with 
a hypofractionated scheme. Regional nodal radiation was deliv‑
ered in 15% of patients, and the dose range was 45.0‑50.4 Gy 
in 25 fractions. A boost to the lumpectomy cavity of 10‑16 Gy 
was received by 88% of patients. These patients had 35% of 
V105% and 16% of V110% (15). Giri et al (16) compared three 
techniques (VMAT, FIF and W methods) in 20 patients, and 
indicated that VMAT is a superior method compared with the 
other two methods. The authors reported that V105% for PTV 
using VMAT was 3.3±5.5%. Our V105% using the FIF w/ 2RP 
method was better than this value. Osei et al (17) conducted 
a dose‑volumetric analysis for the normalized PTV_eval for 
patients treated with hybrid inverse planned IMRT technique 
(50‑Gy dose in 25 fractions). The mean PTV_eval V105% 
was 0.81% for all patients with a mean breast separation of 
22.21 cm, whereas the mean PTV_eval V105% was 0.37% 
for patients with a mean breast separation <20 cm. Compared 
with these results and with the use of the FIF w/o 2RP method, 
the use of the FIF w/ 2RP method resulted in values of PTV 
V105% as low as 0.09%.
The impact of the irradiation method used on dose 
distribution to target volumes was further elucidated by the 
significantly strong associations in high‑dose regions, particu‑
larly in the FIF w/o 2RP method vs. FIF w/ 2RP method group, 
confirming that our method significantly decreases high‑dose 
region volumes.
As for OARs, particularly dose distribution in the heart, 
Duma et al (18) assessed the heart dosimetry parameters in 
patients with breast cancer using 3D‑CRT by tangential fields, 
half beam technique. For a group of patients with an estimated 
low dose to the heart, the authors reported a median MHD to 
the whole heart of 2.6 Gy (0.8‑3.5 Gy), V10 of 3.4% and V20 
of 2.5% (18). The values reported in our study are lower, thus 
improving dose distribution in the heart and lowering the risk 
of late cardiac radiation injuries. Beaton et al (19) identified 
all cardiovascular deaths in women with early‑stage breast 
cancer treated with breast/chest wall RT. The authors found 
that the radiation‑induced cardiac death at 10 years was low 
if MHD is <3.3 Gy, maximum LAD dose is <45.4 Gy and 
V25 <5% (19). For each of the three used irradiation methods, 
our study calculated the percentage of patients receiving 
MHD <3.3 Gy and maximum LAD dose <45.4 Gy. It was 
found that the FIF w/ 2RP method had higher percentage of 
cases with MHD <3.3 Gy (86.1%) and higher percentage of 
cases with maximum LAD dose <45.4 Gy (86.9%) compared 
with those subjected to the W and FIF w/o 2RP methods, thus 
suggesting that FIF w/ 2RP might be a better method to reduce 
radiation‑induced cardiac death at 10 years.
For dose distribution in the lung, Chung et al (20) reported 
that the dosimetric parameter MLD using the partially wide 
tangent technique is correlated with the incidence of radiation 
pneumonitis. There was a statistically significant difference in 
the incidence of radiation pneumonitis between patients who 
had an MLD of 17.9±3.2 and patients who had an MLD of 
19.3±2.8. The MLD was significantly different between total 
radiation pneumonitis grade 0 and grade ≥1 (P=0.042). MLD 
of 20.5 Gy was determined as the cut‑off point for the inci‑
dence of radiation pneumonitis. However, the average value 
of V20 and V30 showed no statistically significant difference 
in the incidence of radiation pneumonitis. Patients with an 
average value of V20 of 36.1±7.7% and V30 of 31.3±7.1% 
had no radiation pneumonitis (20). Although the FIF w/ 2RP 
method had higher values than the FIF w/o 2RP method, 
these values are still considerably low compared with the 
values reported to have a correlation with the incidence of 
radiation pneumonitis. Therefore, the difference in lung doses 
within the used irradiation methods may not have clinical 
Figure 1. Association between the time course of radiotherapy and skin 
toxicity grade. ǂP<0.05 and ǂǂP<0.001 via Kruskal‑Wallis test; *P<0.05 and 
**P<0.001 via Dunn's test. W, wedge; FIF w/o 2RP, field‑in‑field without 2 
reference points; FIF w/ 2RP, field‑in‑field with 2 reference points; Max, 
maximum skin toxicity grade during the 5 weeks of radiotherapy treatment.
Figure 2. Percentage of patients for each skin toxicity grade according to the 
irradiation methods. The presented skin toxicity grades are the maximum skin 
toxicity grades that occurred during the 5 weeks of radiotherapy treatment. 
*P<0.006 via χ2 test with Bonferroni correction was considered to indicate a 
statically significant difference. W, wedge; FIF w/o 2RP, field‑in‑field without 
2 reference points; FIF w/ 2RP, field‑in‑field with 2 reference points.
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significance. Yang et al (21) compared wedge and FIF IMRT 
techniques in patients with small‑sized breasts. The authors 
suggested that the conventional FIF method has favorable 
dose conformity and is an optimal method in patients with 
breast volume ≤350 cm3. Using the conventional FIF method, 
the authors reported a lung V20% of 14.42±2.61% and a heart 
V25% of 2.44±1.07% (21). Although our patients had a mean 
breast volume of 493±247 cc using the FIF w/ 2RP method, 
our results indicated a similar value for the lung V20% of 
14±5% and a lower value for the heart V20% of 1.6±1.5%. 
Morganti et al (22), using a forward FIF IMRT technique for 
201 patients with a mean breast volume of 528 cc, reported that 
V107% of the irradiated volume was 2.4%, which is higher 
than the 0% value observed in our patients treated with the FIF 
w/ 2RP method. The authors also reported MLD and MHD 
values of 9.1 and 3.4 Gy, respectively, whereas our FIF w/ 2RP 
method could reduce the MLD and MHD to 7.7 and 2.5 Gy, 
respectively.
The existence of a high‑dose range in the irradiation field 
and its association to skin toxicities is reported in the litera‑
ture (6‑8). Chen et al (7) reported that, for patients treated with 
BCS, higher volume receiving PTV‑V107% >31.5% and treated 
volume TV‑V110% >4.37% were associated with higher inci‑
dence of acute radiation dermatitis. These reported values are 
significantly higher than 0% of V107% for PTV in our patients 
treated with FIF w/ 2RP. According to Vicini et al (6), the 
breast volume V105% and V110% are significantly associated 
with increasing skin toxicities. Using 3D treatment planning 
and intensity modulation with an MLCs technique, the authors 
found a significant association between median breast volume 
V105% of 11% and increasing skin toxicities. In our study, 
using the FIF w/ 2RP method, the mean V105% for breast 
volume was reduced to 0.1%.
Considering the reported association between high‑dose 
range and skin toxicities, lowering high‑dose areas is likely to 
reduce the occurrence of radiation dermatitis and its severity. 
In view of the comparison of the FIF w/ 2RP method with 
the W and FIF w/o 2RP methods and literature reports, our 
method proved to reduce high‑dose areas, notably V105% 
of the target and doses at OARs. Therefore, the FIF w/ 2RP 
method is expected to diminish skin toxicities.
The awareness of appearance and timing of skin toxicities 
is crucial to ensure an effective management of patients. The 
acute phase of radiation dermatitis typically occurs within 
30 to 90 days of RT treatment (9). Our study evaluated the 
association between the time course of RT and skin toxicity 
grade. Although the FIF w/ 2RP method had a less significant 
impact on skin toxicity grade by the end of the RT treatment 
compared with that of the other two irradiation methods, it 
had a substantial impact during the 3rd and 4th weeks. This 
is particularly beneficial for the patient, since the appearance 
of radiation dermatitis can lead to treatment interruptions or 
cessation (23).
To further assess the impact of the FIF w/ 2RP method on 
skin toxicities, the maximum skin toxicity grade during the 
5 weeks of RT treatment was examined for the three irradiation 
methods used, in addition to the skin toxicity grades reported 
in the literature. Tortorelli et al (8) reported, for patients 
who underwent irradiation with conventional fractionation 
followed by an electron tumor bed boost, the maximum acute 
toxicity during or after completion of RT using the RTOG 
Acute Morbidity Scale. Grades 1, 2 and 3 acute skin toxicities 
were registered in 45.2, 42 and 13% of patients, respectively. 
Borm et al (5) evaluated 255 patients treated with tangential 
3D‑CRT and prescribed doses of 50.4 or 50.0 Gy, followed by 
a sequential boost to the tumor bed for 92.5% of the patients, 
using the CTCAE V.4.0 scale. By the end of the treatment, skin 
toxicity grade 1 was observed in 42.4% of patients, grade 2 in 
55.7% and grade 3 in 2%. Wright et al (15) reported that, in 
patients treated only with conventionally fractionated irradia‑
tion, 42% developed CTCAE grade 0‑1 skin toxicity and 58% 
developed grade 2‑3. Vicini et al (6) reported that, using the 
MLCs IMRT technique, a prescribed dose of 45 Gy followed 
by a supplemental boost to the tumor bed of 16 Gy, a total of 
56% of patients experienced RTOG grade 0 or 1 acute skin 
toxicity, while 43% experienced grade 2 acute skin toxicity and 
only 1% experienced grade 3 toxicity. In our study, compared 
with the observations in the W and FIF w/o 2RP methods, for 
patients treated with the FIF w/ 2RP method, the skin toxicity 
was reduced, since 5.5% experienced grade 0, 91.3% grade 1, 
3.2% grade 2 and none grade 3. This clinical outcome supports 
that FIF w/ 2RP is a useful method to reduce both high‑dose 
areas and acute skin toxicity.
Previous studies identified predictive factors for acute 
skin toxicities and categorized them into patient‑related 
factors and treatment procedure‑related factors. Our study, 
through the evaluation of association between these factors 
and skin toxicity, demonstrated that the irradiation methods 
have a greater impact on skin toxicity compared with the 
patients' baseline characteristics. Breast size was reported as 
a predictive factor for acute skin toxicity (9). In our study, the 
correlations between breast volume and skin toxicity grade 
Table IV. Association between irradiation methods and skin toxicity grade.
Variable All irradiation methods W vs. FIF w/o 2RP W vs. FIF w/ 2RP FIF w/o 2RP vs. FIF w/ 2RP
Skin toxicity grade
    Week 3 0.46a 0.12b 0.49a 0.38a
    Week 4  0.33a 0.10 (P=0.07) 0.33a 0.25a
    Max week (0‑5) 0.11b 0.03 (P=0.58) 0.10b 0.09 (P=0.09)
The data are presented as the η values. aP<0.001 and bP<0.05 via Eta correlation ratio test. W, wedge; FIF w/o 2RP, field‑in‑field without 2 
reference points; FIF w/ 2RP, field‑in‑field with 2 reference points.
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throughout RT treatment, although markedly weak, they were 
significant. Separation, PTV volume and weight also had a 
markedly weak, but significant impact on the skin toxicity 
maximum grade during the 5 weeks of RT treatment, whereas 
tumor site had significant impact at weeks 3 and 4. Overall, the 
effect of the patients' baseline characteristics on skin toxicity 
was limited, while the irradiation methods effect, particularly 
that of the FIF w/ 2RP method, was comparatively substantial. 
Associations with the skin toxicity grade were significant 
when comparing the FIF w/ 2RP method vs. the W or the FIF 
w/o 2RP methods, indicating that a significant decrease in skin 
toxicity grade might be expected when using the FIF w/ 2RP 
method. The utmost benefit of our method can be perceptible 
during the RT treatment at weeks 3 and 4, as skin toxicity 
grade is significantly improved compared with that of the W 
and to the FIF w/o 2RP methods. This decline in skin toxicities 
during the treatment course minimizes risks of interruption or 
cessation and provides patient comfort.
Assessment of skin toxicities is of a subjective nature; 
however, in our institution, the skin toxicity grade was 
evaluated by a single experienced radiation oncologist with 
a standardized approach, which reduces potential variations 
and ensures a reproductible quantification. The FIF w/ 2RP 
method is a clinically practical and achievable method; 
nevertheless, it is more time consuming than conventional 
irradiation methods. Furthermore, the impact of this method 
is more considerable in patients with small‑sized breasts; 
therefore, this aspect should be taken into consideration when 
selecting the appropriate irradiation method.
In conclusion, our study confirmed that the FIF w/ 2RP 
method decreased the high‑dose range V105% of the target 
to 0%, while maintaining a homogeneous dose distribution 
across the breast tissue. This decrease in high‑dose range was 
in conjunction with a decrease in the occurrence and grade 
of skin adverse events. Therefore, the FIF w/ 2RP could be 
advised as an optimal method in clinical practice for patients 
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